View all adult cancer types
View all pediatric cancer types
Susan F. Smith Center for Women's Cancers
Gynecologic CancerBlood CancersCancer Genetics and PreventionCutaneous (Skin) CancerGastrointestinal CancerGenitourinary CancerHead and Neck CancerHematologyMelanomaNeuro-OncologySarcomaStem Cell TransplantThoracic (Lung) Cancer
Blood DisordersBrain TumorsHematologic MalignanciesSolid TumorsStem Cell Transplant
U.S. News and World Report ranks Dana-Farber/Brigham and Women's Cancer Center the top hospital in New England for the 14th straight year.
Dana-Farber Cancer Institute has earned Magnet® status from the American Nurses Credentialing Center (ANCC) for the third time. This prestigious designation recognizes excellence in nursing and health care delivery.
In an affirmation of worldwide respect for the impact of Dana-Farber research, 19 basic scientists and clinical investigators at the Institute have been listed among "the world's most influential scientific minds." The ranking was based on how frequently their research discoveries have been cited by peers in the past decade.
Dana-Farber Cancer Institute is recognized as a Magnet® organization for excellence in nursing and patient care for the third time.
Dana-Farber scientists identify a protein that is a cause of cachexia, a severe wasting of fat and muscle in half of all cancer patients, and show that blocking the protein in mice can prevent or halt the debilitating condition.
Dana-Farber and colleagues from the Cancer Genome Atlas (TCGA) Research Network identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, potentially identifying a greater number of patients with treatable mutations because many potent cancer drugs that target these mutations already exist. Additionally, these findings may expand the number of possible new therapeutic targets for this disease.
The U.S. News and World Report Best Hospitals Guide has ranked Dana-Farber/Brigham and Women's Cancer Center the highest in New England for cancer care for the 14th straight year and fourth overall in the country.
An editorial written by physicians at Dana-Farber supports a study showing there is no compelling evidence to justify using testosterone suppression therapy on men with early-stage prostate cancer.
E. Krop led a study showing that the anti-body drug ado-trastuzumab emtansine
significantly prolonged progression-free survival in patients with progressive
HER2-positive advanced breast cancer.
Eric P. Winer co-chaired an expert panel that developed a clinical practice
guideline on disease management for patients with advanced HER2-positive breast
cancer and brain metastases.
Dr. Matthew Meyerson
led a genomic study of lung cancer which has provided information that could
help scientists devise new treatments.
Paul L. Nguyen led a study showing prostate cancer patients with health
insurance are less likely to have metastatic disease or die from the
cancer than those without health insurance.
Robert Haddad commented on JPMorgan Chase CEO Jamie Dimon being diagnosed with throat cancer.
Tai Chi for Optimal Health
3:00 PM - 4:30 PM
Smith Room, 330, Stoneman Patient Services Suite
An internal Chinese martial art practiced for both defense training and health benefits. Learn sitting and standing techniques as well as slow moving meditation. Open to patients and family members. Please register at 617-632-3322.
4:30 PM - 6:00 PM
Smith Room 330, Stoneman Patient Services Suite
Fine tune your mind/body skills and create balance among them. Open to patients and family members. Please register at 617-632-3322.
Melanoma Support Group(6)
5:30 PM - 7:00 PM
This group offers you can opportunity to develop a peer network of shared understanding and support in a setting where you can discuss;
Pre-registration is required: To register or for more info: Contact Nancy Bailey at 617-632-3599
Deaconess Medical Center. Call Frank McCaffrey 617 667-3525
Patient referral information, clinical resources and more.
For adults:877-442-3324For children:888-733-4662Or complete the online form.
Search current cancer clinical trials at Dana-Farber.
There are many ways to support Dana-Farber and the Jimmy Fund.
More ways to helpGiving Catalog
Insight features the latest in cancer care and research news from Dana-Farber.Read the blog
Stay current on the latest news by signing up for Spotlight, our email newsletter.View current issueSubscribe now
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: